ANRO vs OVID
ANRO: Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted therapies. OVID: A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental epileptic encephalopathies, and psychosis.
Side-by-side fundamentals
| Metric | ANRO | OVID | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $28.63 | $2.37 | |
| Market cap as of 2026-07-31 | $1.0B | $442M | |
| PEG as of 2026-07-31 | -1.79 | n/a | |
| Net margin as of 2026-07-31 | -4374.8% | -240.1% | OVID higher |
| Operating margin as of 2026-07-31 | -5740.9% | -585.2% | OVID higher |
| ROE as of 2026-07-31 | -47.2% | -22.5% | OVID higher |
| ROA as of 2026-07-31 | -38.8% | -18.7% | OVID higher |
| Debt / equity as of 2026-07-31 | 0.08 | 0.00 | OVID lower |
| Revenue growth (YoY) as of 2026-07-31 | n/a | +1199.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +69.0% | |
| Beta as of 2026-07-31 | 0.95 | 1.51 | |
| 1-year return as of 2026-07-30 close | +832.6% | +374.0% | ANRO higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.